DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

Dexcom's survey of more than 800 healthcare professionals and 2,500 Type 2 diabetes patients identified a sizable CGM growth opportunity: 55% of patients reported limited knowledge of CGM, while reimbursement barriers were cited by 90% of U.S. healthcare professionals. Among Type 2 patients using GLP-1 medicines, 58% also use CGM, versus 27% of non-insulin users, supporting potential demand expansion as GLP-1 adoption rises. The opportunity is tempered by reimbursement constraints and intensifying competition from Abbott's Libre platform and MiniMed's integrated CGM-pump offerings.

Analysis

The investable issue is not awareness but payer conversion. Incremental non-insulin Type 2 users carry lower clinical urgency and likely lower persistence than intensive-insulin users, so any expansion can lift sensor volumes while diluting revenue per patient and raising commercial-acquisition costs. Dexcom's survey is directional marketing evidence rather than proof of changed reimbursement or prescription behavior; absent a coverage decision, it should not alter near-term estimates.

ABT is better positioned for a broadening category because its lower-friction consumer/wellness adjacency, ketone-monitoring differentiation, and installed base allow it to monetize CGM adoption across medical and non-medical channels. DXCM retains a premium technology and data-platform case, but faces a more difficult margin tradeoff if it must discount to gain access in the large Type 2 cohort. The less obvious beneficiary is NVO: CGM-derived feedback can improve persistence and reinforce outcomes-based conversations with payers, though it is unlikely to be material to drug revenue within 12 months.

Over the next 1-3 months, watch U.S. commercial-payer policy updates, Medicare coverage expansion, and management disclosure of Type 2 new-patient mix versus sensor pricing. A reimbursement-led inflection would justify estimates rising across both DXCM and ABT over 6-18 months; promotional partnerships alone will not. Contrarian risk: effective GLP-1 treatment may reduce the perceived need for continuous monitoring among cash-pay patients, making the observed overlap a selection effect rather than evidence of incremental demand.

The cleaner expression is relative rather than outright: ABT has more diversified earnings support if reimbursement remains slow, while DXCM has greater upside only if access broadens without price concessions. Thesis fails for the ABT/DXCM relative trade if Dexcom demonstrates sustained Type 2 growth with stable realized sensor revenue, or if Abbott's CGM growth decelerates despite product launches.

Key Decisions for Investors

• Maintain a 6-12 month long ABT / short DXCM relative position, sized beta-neutral, pending next earnings: favor ABT's broader monetization channels and lower single-category valuation risk. Cover if DXCM reports Type 2 new-start growth above guidance while keeping realized revenue per user stable for two consecutive quarters.
• Do not add outright DXCM on this report. Set an entry alert around a documented U.S. payer or Medicare eligibility expansion; initiate only if management pairs it with unchanged gross-margin or pricing guidance, targeting a 12-18 month rerating from durable addressable-market expansion.
• Monitor NVO prescription persistence and payer contracting for explicit CGM-linked care pathways over the next two quarters. Treat this as an earnings-quality watch item rather than a standalone NVO catalyst until a commercial program discloses enrolled patients or reimbursement economics.
• Avoid using MDT as a read-through for the described CGM/pump opportunity without confirmation of the post-separation entity's listed ticker, financial exposure, and supply agreement economics; the supplied MMED identifier requires verification before trading.